Why Schedule III Is Not Enough: The Case for Cannabis Descheduling
Advertisement
In December 2025, President Trump signed an executive order directing the Drug Enforcement Administration to reschedule cannabis from Schedule I to Schedule III [Quick Definition: A mid-level federal drug classification including ketamine and testosterone] under the Controlled Substances Act. While this move represents the most significant federal cannabis policy shift in modern history, many cannabis advocates are sounding an important alarm: Schedule III rescheduling, though meaningful, falls dramatically short of what's needed for true cannabis reform. Understanding the distinction between rescheduling and descheduling is essential for anyone invested in the future of cannabis policy in America.
Table of Contents
- What Schedule III Actually Means
- The Critical Distinction: Rescheduling Is Not Legalization
- The Banking Problem Persists
- What Schedule III Cannot Do: The Record Expungement Question
- State Autonomy: The Fundamental Problem
- Descheduling: The Real Solution
- The Congressional Role
- Moving Forward
What Schedule III Actually Means
Under the Controlled Substances Act, scheduling determines both a drug's legal status and its research accessibility. Schedule III drugs are defined as substances with accepted medical uses and moderate-to-low potential for dependence. Other Schedule III drugs include steroids, ketamine for medical purposes, and certain barbiturates.
Moving cannabis to Schedule III acknowledges that it has legitimate medical applications and lower abuse potential than heroin or cocaine, which remain in Schedule I.
The rescheduling provides real, tangible benefits that shouldn't be minimized. Schedule III status eliminates Section 280E [Quick Definition: IRS code barring cannabis businesses from deducting normal expenses like rent and payroll] of the Internal Revenue Code, which has forced cannabis businesses to pay income taxes on their gross revenue while denying them standard business deductions. For a typical state-licensed dispensary operating in compliance with state law, this tax burden costs approximately $800,000 annually.
Removing that burden would provide immediate financial relief to the legal cannabis industry and free up capital for compliance, research, and product development.
Rescheduling also makes it easier for researchers to obtain Schedule III cannabis for clinical trials and studies. Under Schedule I, researchers face bureaucratic hurdles and must obtain specific DEA approvals before conducting any research. Schedule III status streamlines this process, potentially accelerating scientific understanding of cannabis's medical applications and therapeutic potential.
This is particularly important for researchers investigating cannabis's role in treating chronic pain, anxiety, epilepsy, and other conditions.
The Critical Distinction: Rescheduling Is Not Legalization
Here's where the critical distinction emerges. Despite the positive changes that Schedule III rescheduling brings, it absolutely does not legalize cannabis at the federal level. This is perhaps the most misunderstood aspect of the recent executive order, and it's crucial for consumers and business owners to understand this limitation.
Under Schedule III, cannabis remains illegal to produce, distribute, and possess at the federal level. People who produce or dispense marijuana in compliance with state laws could still face federal prosecution. This isn't theoretical—the federal government has prosecuted individuals and businesses operating legally under state law before, and Schedule III status doesn't eliminate this risk.
If a future administration changes direction or if Congress fails to pass supporting legislation, federal agents could theoretically conduct raids on state-licensed dispensaries and charging operators with federal crimes.
Schedule III rescheduling does not create interstate commerce in cannabis. If you own a dispensary in Colorado with surplus inventory, you cannot legally transport that product across state lines to sell it in an adjacent state, regardless of that state's legalization status. Federal law still prohibits this interstate activity, and the Controlled Substances Act remains in place.
For consumers, this means prices and availability remain fragmented by state, with no ability for interstate supply chains to equalize costs or ensure consistent access.
The Banking Problem Persists
Many people assume that Schedule III will solve the persistent cannabis banking crisis. This is not the case. While rescheduling may provide some confidence to financial institutions, the banking problem fundamentally requires congressional action, specifically passage of the SAFER Banking Act (Secure and Fair Enforcement of Regulated Clubs).
As long as cannabis remains scheduled—even at Schedule III—banks face potential liability under federal money laundering and kingpin statutes if they provide services to cannabis businesses.
This means that even with Schedule III status, many cannabis businesses will continue operating largely in cash. They'll struggle to open business accounts, secure loans, or access conventional financial services. The absence of banking access creates security vulnerabilities, complicates tax reporting, makes business expansion difficult, and perpetuates the cash-based inefficiency that has plagued the cannabis industry since legalization began.
What Schedule III Cannot Do: The Record Expungement Question
Another area of confusion centers on criminal records. Many people hope that rescheduling will automatically lead to the expungement of prior cannabis convictions. Schedule III status does not trigger automatic expungement of records for people previously convicted of cannabis offenses.
Those decisions remain within the purview of individual states and require separate legislative action or executive clemency. While some states may choose to use rescheduling as an opportunity to reform their expungement laws, there is no federal mechanism under Schedule III that automatically erases prior cannabis convictions.
This is particularly important for those who suffered under decades of cannabis prohibition. Even as the industry enjoys rapid expansion and legitimacy, countless individuals remain burdened by criminal records that affect employment, housing, education, and voting rights. Schedule III status does nothing to address this injustice.
State Autonomy: The Fundamental Problem
The core issue underlying all these limitations is that Schedule III does not grant states the autonomy to regulate cannabis the way they regulate alcohol. Under the 21st Amendment, alcohol is legal at the federal level, giving states broad authority to craft their own regulatory frameworks. States can set age restrictions, distribution methods, taxation, and licensing frameworks without worrying that federal law contradicts their efforts.
Cannabis remains different. Even under Schedule III, states are technically violating federal law by legalizing cannabis.
This ambiguity creates legal vulnerabilities and policy constraints that wouldn't exist with descheduling. A Schedule III alcohol is not a hypothetical—it's a recognition that the substance can be legally regulated at the state level without federal interference or legal risk. Schedule III cannabis lacks that clarity.
Descheduling: The Real Solution
For true cannabis reform that grants states the autonomy enjoyed by alcohol regulators and eliminates federal prosecution risks, cannabis must be descheduled entirely—removed from the Controlled Substances Act. Descheduling would place cannabis in the same category as alcohol and tobacco: substances regulated by states but not subject to federal scheduling restrictions.
Descheduling doesn't mean a free-for-all. It simply means that cannabis policy becomes a matter of state regulation rather than federal classification. States could still impose age restrictions, licensing requirements, quality controls, and taxation.
The difference is that these state regulations would be legally supported by federal law rather than existing in an uncomfortable gray zone.
Several organizations, including NORML, have called for descheduling as the ultimate goal of federal cannabis reform. Additionally, Hawaii has introduced a resolution calling on Congress to deschedule cannabis entirely, demonstrating that this isn't a fringe position but rather an increasingly mainstream policy viewpoint.
The Congressional Role
The executive order directing rescheduling is important, but it operates within the DEA's authority to schedule and reschedule substances. For true legalization and descheduling, Congress must act. Some lawmakers have proposed legislation that would deschedule cannabis, but these bills face political hurdles in a divided Congress.
Schedule III rescheduling, while less than ideal, may be the executive branch's maximum power without Congressional support.
Moving Forward
The rescheduling to Schedule III is a victory for cannabis reform advocates, and its benefits are real and immediate. The 280E tax burden relief alone represents a massive win for the cannabis industry. Easier research access will advance scientific understanding.
But consumers, advocates, and business owners should understand that Schedule III is a waypoint, not the destination. Full legalization and the removal of cannabis from the Controlled Substances Act entirely remain necessary for complete federal alignment with state-legal cannabis markets and for the elimination of federal prosecution risks.
As more states embrace cannabis legalization and more Americans recognize cannabis's medical and recreational value, pressure will build for Congress to deschedule cannabis entirely. Until that happens, the cannabis industry operates in a federally-tolerated gray zone. Schedule III rescheduling improves that situation significantly, but true reform requires federal descheduling.
Pull-Quote Suggestions:
"Many people assume that Schedule III will solve the persistent cannabis banking crisis."
"For a typical state-licensed dispensary operating in compliance with state law, this tax burden costs approximately $800,000 annually."
"Here's where the critical distinction emerges."
Why It Matters: Schedule III rescheduling won't legalize cannabis. Here's why full descheduling is necessary for true reform.